Clinical Trial Update: Gefitinib in Treating Patients With Malignant Mesothelioma [Phase 2]

View source ↗

Summary

Gefitinib was studied in a Phase 2 trial for malignant mesothelioma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Mesothelioma
• Malignant Mesothelioma
• Sarcomatous Mesothelioma

Drugs mentioned

• Gefitinib (Gefitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Mesothelioma, Epithelial Mesothelioma | Phase 2 | Status: COMPLETED